Stocks
Heron Therapeutics (HRTX) EBITDA margin US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -249.3% | -164.1% | -81.7% | -3.50% | -11.5% | -13.6% | ||
| Changes by years, y/y, % | +2pp | +85pp | +82pp | +78pp | -8pp | -46.0% | |||
Heron Therapeutics. EBITDA margin, %
Heron Therapeutics. EBITDA margin, changes, pp
Heron Therapeutics (HRTX) EBITDA margin US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | 9.52% | -2.76% | -36.6% | -1.95% | -13.7% | -13.6% | |
| Changes by years, y/y, % | +21pp | +13pp | -25pp | -23pp | -23pp | |||
| Changes by quarters, q/q, % | -12pp | -12pp | -34pp | +35pp | -12pp | |||
